The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Study achieves primary endpoint of radiographic progression-free survival
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Subscribe To Our Newsletter & Stay Updated
